Biotech
Commented by Stefan Feulner on October 22nd, 2026 | 05:25 CEST
BioNTech, Formycon, Biogen: Pharma billions are being redistributed
The pharmaceutical industry is facing a massive restructuring. As blockbuster drugs worth billions lose patent exclusivity, cheaper copycat products are entering the market. At the same time, biotech groups are investing billions in new cancer drugs and therapies for diseases that have long been difficult to treat. For investors, this creates tension between established revenue generators, new active ingredients and rising healthcare costs. Companies that secure access to lucrative drug markets early are particularly interesting. Even a small share of a global blockbuster's revenue can have considerable economic significance.
Read
Commented by Stefan Feulner on October 21st, 2026 | 05:38 CEST
Regeneron, Vidac Pharma, Krystal Biotech: New Active Ingredients, Enormous Stock Market Potential
Cancer treatment is undergoing a fundamental transformation. Rather than relying solely on conventional chemotherapy, new approaches increasingly target the biological mechanisms that drive tumours. In particular, immunotherapies, gene therapies and interventions targeting cellular metabolism are opening up new possibilities for treating skin cancer. As approved medicines reach more patients, innovative biotech companies face key clinical milestones. Commercial opportunities are substantial, as demand for effective, well-tolerated treatments continues to grow. The decisive factor will be which technologies can confirm their promising results in larger clinical trials.
Read
Commented by Stefan Feulner on October 20th, 2026 | 05:23 CEST
AstraZeneca, Cardiol Therapeutics, Kiniksa – New hope for heart patients
Cardiovascular diseases remain among the greatest medical challenges worldwide. While established pharmaceutical groups invest billions in new active ingredients and artificial intelligence, specialised biotech companies are developing targeted therapies for conditions that have so far been difficult to treat, such as recurrent pericarditis. Patients often suffer from painful relapses and require long-term treatment. New medicines could fundamentally change how these conditions are managed. For investors, this brings into focus companies that already market approved products or are awaiting pivotal clinical trial results.
Read
Commented by Lars Winter on October 13th, 2026 | 05:22 CEST
BioNxt, CrowdStrike and Shell: Three exciting stocks ahead of the next price surge
On the stock market, facts matter most. New study results, strong figures and solid operational records tend to attract investor attention and often drive share prices higher. These three stocks deserve a closer look: BioNxt Solutions is approaching its first human study, CrowdStrike has reported a record quarter, and Shell is benefiting from exceptionally high refining margins. Three very different stocks, each offering opportunities alongside distinct risks. We take a closer look at these compelling names in our stock check.
Read
Commented by Fabian Lorenz on October 12th, 2026 | 05:30 CEST
After 600% Gains with Moderna! Cardiol Therapeutics Poised for a Revaluation - Analysts See Significant Upside Potential
With gains of more than 600%, Moderna is the Nasdaq’s best-performing stock so far this year. Much of its future growth potential may already be priced in, prompting Citigroup to recommend selling shares in the mRNA specialist. Analysts, however, see significant upside potential in another biotech company: Cardiol Therapeutics. The Canadian biotechnology company focuses on inflammatory heart diseases, and its lead drug candidate, CardiolRx™, is already in Phase 3 clinical trials. Following strong Phase 2 data, the stock more than doubled between July and September. After a subsequent pullback, could this present an attractive entry opportunity? In a recent interview, the CEO explains why he remains optimistic. Two research firms recommend buying the stock and see the potential for a multiple-fold increase in its share price.
Read
Commented by Carsten Mainitz on October 12th, 2026 | 05:28 CEST
Don’t Miss Out! Cancer Research and Comeback Potential: Vidac Pharma, Bayer and Evotec in Focus!
New cancer therapies are targeting major medical breakthroughs. For investors, however, the key question is when scientific progress will begin to translate into rising share prices. Vidac Pharma is at a particularly exciting stage in its development. The company is awaiting crucial clinical trial data that could validate its innovative approach to cancer cell metabolism and mark a major milestone. Bayer is expanding its oncology business but must also contend with a range of challenges. Meanwhile, Evotec needs to prove it can turn its research, technology platforms, and strategic partnerships into profitable business opportunities while rebuilding lost investor confidence. Which developments could now trigger a revaluation of these three stocks?
Read
Commented by André Will-Laudien on October 9th, 2026 | 10:59 CEST
BioTech Rally 2027: Patents, Blockbusters and Biosimilars! The spotlight is on Bayer, Formycon, Evotec and Novo Nordisk
The storm in the pharmaceutical sector continues to gain momentum! Expiring patents and struggling healthcare systems are shaking up old, high-margin blockbuster drugs, as societal changes and government budget constraints shake the foundations of costly pharmaceutical development. As patents expire, many generic manufacturers find themselves in a race against time. Market shares are being reshuffled, heralding a new era of growth. Amid this dynamic rally, four well-known industry players are positioning themselves on different fronts to capitalize on the market shifts. After several difficult years, the Leverkusen-based pharmaceutical giant Bayer is fighting its way back with a completely revamped pipeline. Also in the fast lane is the German biosimilar hopeful from Munich, with its first products already on the market. At Hamburg-based drug discovery company Evotec, restructuring is still underway; the key driver is its state-of-the-art, AI-powered multivalent platform. Meanwhile, the Danish giant Novo Nordisk continues to ride the global obesity and diabetes wave, driving forward the next generation of its blockbuster drugs. Analysts do not have it easy, but there are plenty of opportunities for investors.
Read
Commented by Carsten Mainitz on October 9th, 2026 | 09:05 CEST
Weight-Loss Drugs 2.0: Can BioNxt and Merck Catch Up with Novo Nordisk and Eli Lilly? What About BioNTech?
The boom in weight-loss drugs is creating a billion-dollar market within the pharmaceutical industry, with an annual volume of USD 100 billion. Novo Nordisk and Eli Lilly are battling for dominance, while Merck is also entering the fray, albeit still in the early stages. BioNxt Solutions aims to deliver established active ingredients via a dissolvable film, targeting enormous potential with a comparatively low-risk approach. For BioNTech, a substantial cash reserve will determine how much time the company has to deliver its next growth spurt. Where does the greatest stock-market opportunity lie?
Read
Commented by Carsten Mainitz on October 7th, 2026 | 08:40 CEST
Spot the Next Stock Catalyst Early: Key Milestones for Lahontan Gold, Evotec and Deutz
Get in before the stock takes off! The key is to identify the trigger for the next share-price move early enough. Lahontan Gold is working to restart a historic gold mine in Nevada and recently made an attractive acquisition. Biotech company Evotec is fighting to turn its operations around and rebuild investor confidence. Deutz is expanding its industrial business into energy and defense, taking the company into new dimensions of growth. What does this mean for investors? Where are the most compelling opportunities for stock pickers?
Read
Commented by Fabian Lorenz on October 7th, 2026 | 08:35 CEST
Time to Sell Moderna Stock After a 200% Rally? A Comeback for Standard Lithium and HPQ Silicon?
Moderna's stock has had a spectacular run in recent weeks. Since mid-August, the biotech company's stock has surged from USD 63 to over USD 200. But now analysts are pouring cold water on the price surge. In their view, the stock could more than halve in value. While Moderna has already made a successful comeback, there are good reasons to believe that HPQ Silicon's is still to come. Despite positive news flow, the stock has yet to take off. Following successes in the drone sector, the company recently laid the groundwork to market its technology for producing fumed silica. Investors have been waiting for a comeback from Standard Lithium for quite some time. The stock is trading at a yearly low and approaching penny stock levels. Yet the company recently secured a new customer.
Read